Pediatr. pro Praxi, 2005; 2: 88-92

CURRENT VIEW ON THE PATHOGENESIS AND MANAGEMENT OF ATOPIC DERMATITIS

MUDr. Dušan Buchvald Ph.D
Detská dermatovenerologická klinika DFNsP a LF UK, Detská fakultná nemocnica, Bratislava

A precise understanding of the genetic, metabolic and immunologic mechanisms is crucial for development of effective treatment strategies for atopic dermatitis. Various studies indicate that it has a multifactorial cause, with activation of complex immunologic and inflammatory pathways. Treatment of atopic dermatitis requires a comprehensive approach that includes evaluation of potential triggers and education of the patient and family regarding proper avoidance measures. Hydration of the skin and maintenance of an intact skin barrier remain integral to proper management. Although topical corticosteroids have been a mainstay of anti-inflammatory therapy, the newer topical calcineurin inhibitors offer advantages for treatment of this chronic, relapsing disease.

Keywords: Key words: atopic dermatitis, etiopathogenesis, therapy.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Buchvald D. CURRENT VIEW ON THE PATHOGENESIS AND MANAGEMENT OF ATOPIC DERMATITIS. Pediatr. praxi. 2005;6(2):88-92.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Akdis M, Trautmann A, Blaser K, Akdis CA. T cells and effector mechanisms in the pathogenesis of atopic dermatitis. Curr Allergy Asthma Rep 2002; 2: 1-3. Go to original source... Go to PubMed...
    2. Akhavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 2003; 21: 225-240. Go to original source... Go to PubMed...
    3. Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder J-F, Thestrup-Pedersen K. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol 2004; 151 (suppl 70): 3-27. Go to original source... Go to PubMed...
    4. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 2003; 112: S140-S150. Go to original source... Go to PubMed...
    5. Bousquet J, Lockey R, Malling HJ (eds.). WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 (suppl. 44): 1-42. Go to original source... Go to PubMed...
    6. Bowcock AM, Cookson WOCM. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. Hum Mol Genet 2004; 13: R43-R55. Go to original source... Go to PubMed...
    7. Fartasch M, Bassukas ID, Diepgen TL. Disturbed extruding mechanism of lamellar bodies in dry non-eczematous skin of atopics. Br J Dermatol 1992; 127: 221-7. Go to original source... Go to PubMed...
    8. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995; 105: 84S-88S. Go to original source...
    9. Hara J, Higuchi K, Okamoto R, Kawashima M, Imokawa G. High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis. J Invest Dermatol 2000; 115: 406-413. Go to original source... Go to PubMed...
    10. Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-684. Go to original source... Go to PubMed...
    11. Jensen JM, Folster-Holst R, Baranowsky A, Schunck M, Winoto-Morbach S, Neumann C, Schutze S, Proksch E. Impaired sphingomyelinase activity and epidermal differentiation in atopic dermatitis. J Invest Dermatol 2004; 122: 1423-1431. Go to original source... Go to PubMed...
    12. Kawashima M, Tango T, Noguchi T, Inagi M, Nakagawa H, Harada S. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148: 1212-1221. Go to original source... Go to PubMed...
    13. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol 2000; 25: 552-558. Go to original source... Go to PubMed...
    14. Kyllonen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174-1181. Go to original source... Go to PubMed...
    15. Martinez-Moczygemba M, Huston DP. Biology of common ? receptor-signaling cytokines: IL-3, IL-5 and GM-CSF. J Allergy Clin Immunol 2003; 112: 653-665. Go to original source... Go to PubMed...
    16. Meurer M, Fartasch M, Albrecht G, Vogte T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-372. Go to original source... Go to PubMed...
    17. Sidbury J, Hanifin JM. Old, new, and emerging therapies for atopic dermatitis. Dermatologic Clinics 2000; 18: 1-11. Go to original source... Go to PubMed...
    18. Trautmann A, Altznauer F, Akdis M, Simon H-U, Disch R, Brocker E-B, Blaser K, Akdis CA. The differential fate of cadherins during T-cell-induced keratinocyte apoptosis leads to spongiosis in eczematous dermatitis. J Invest Dermatol 2001; 117: 927-934. Go to original source... Go to PubMed...
    19. Warner JO (ETAC study group). A double-blinded randomised placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up. J Allergy Clin Immunol 2001; 108: 929-937. Go to original source... Go to PubMed...

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.